Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy

NCT01896297 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01896297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01896297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Lead sponsor
Boehringer Ingelheim
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2013
Completion date
October 31, 2015
Enrollment
63 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation